Accele BioPharma, Inc.

Accele Biopharma (“Accele”) and Accele Venture Partners, a related special purpose venture fund, were formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking early stage life science technologies that have the potential to dramatically improve human healthcare, have strong commercial promise and have the potential for generating early proof of concept data. To achieve this goal we have assembled an experienced management team, a group of sophisticated investors, a nationally recognized advisory board, excellent research facilities and the broad scientific expertise necessary to evaluate and manage such opportunities. Our approach is capital-efficient in that the management team will manage multiple early stage enterprises simultaneously. Once early preclinical and clinical milestones for a portfolio company are met, the Accele team will facilitate the subsequent financing and the hiring of a management team for a stand-alone company. 

Accele Venture Partners, L.P.

Accele Venture Partners (“AVP”) is a limited partnership formed to invest, together with established institutional life science investors, in the initial funding of life science companies selected and managed by Accele BioPharma, Inc. (“Accele”). Accele intends to evaluate technologies from a variety of sources including referrals from its investor group, established institutional life science investors and Oklahoma Medical Research Foundation (“OMRF”), and technologies originating at academic medical research centers both in Oklahoma and across the nation.  Each company formed will be initially housed in Accele’s facilities in OUHSC Research Park and managed by Accele’s experience management team. AVP anticipates investing up to 30% of its investable funds in the initial funding of such companies with the balance of the fund reserved for follow on investment in companies which meet predefined value-adding milestones. 

Accele is dedicated to supporting groundbreaking approaches to improve human healthcare.
Clayton Duncan, CEO
4
Portfolio Companies
10
Million AVP Fund I
25
Million Total Portfolio Raised
For more information about Accele or our portfolio companies: Contact Us